Compare Adaptive Biotechnologies Corp (ADPT) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs Trip.com Group Ltd — how do they compare? Adaptive Biotechnologies Corp trades at $20.19 (market cap $3.33B), while Trip.com Group Ltd trades at $41.46 (market cap $25.65B). The key difference: Trip.com Group Ltd is far larger — about 7.7× Adaptive Biotechnologies Corp's market cap, and Trip.com Group Ltd pays a 0.57% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | TCOM | |
|---|---|---|
Market Cap | $3.33B | $25.65B |
Sector | Health | Consumer Cyclical |
52-Week High | $22.37 | $78.96 |
52-Week Low | $10.24 | $39.84 |
Enterprise Value | $3.19B | $18.35B |
Dividend Yield | — | 0.57% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $20.82, down 1.75% today, with a bullish technical signal from moving averages and a consensus analyst price target of $20.40. The company announced a strategic separation of its MRD and Immune Medicine businesses in June 2026, alongside a $300 million convertible notes offering to enhance financial flexibility. Revenue grew to $277 million in 2025, though net losses persist at -$59.50 million, with improving margins and cash flow trends showing net positive cash generation of $22.37 million.
Outlook remains cautiously optimistic as the business split aims to unlock value, but execution risks and sustained profitability challenges pose headwinds. Analysts are predominantly bullish (64.71% buy ratings), citing growth in the clonoSEQ MRD segment, yet the stock faces volatility from high valuation multiples and insider selling activity.
Trip.com Group (TCOM) trades at $40.81, down 0.46% on the day, near its 52-week low. The stock shows bearish technical signals with oversold RSI readings. Fundamentally, TCOM reported Q1 2026 revenue growth of 17% year-over-year but missed EPS estimates, with Q2 revenue guidance of 3%-8% growth disappointing investors. The company maintains strong profitability with a 48.65% net margin and attractive valuation multiples, including a P/E of 6.16. Recent news highlights regulatory scrutiny and a significant stock selloff following earnings.
The outlook for TCOM is mixed. Strong cash flow, dominant market position in Chinese travel, and low valuations support upside potential toward the $56.72 analyst target. However, near-term risks include regulatory investigations, margin pressure from cost growth, and bearish technical trends. Investors should weigh solid fundamentals against heightened sentiment risks and guidance concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
